215 related articles for article (PubMed ID: 35025110)
1. Structure- and Interaction-Based Design of Anti-SARS-CoV-2 Aptamers.
Mironov V; Shchugoreva IA; Artyushenko PV; Morozov D; Borbone N; Oliviero G; Zamay TN; Moryachkov RV; Kolovskaya OS; Lukyanenko KA; Song Y; Merkuleva IA; Zabluda VN; Peters G; Koroleva LS; Veprintsev DV; Glazyrin YE; Volosnikova EA; Belenkaya SV; Esina TI; Isaeva AA; Nesmeyanova VS; Shanshin DV; Berlina AN; Komova NS; Svetlichnyi VA; Silnikov VN; Shcherbakov DN; Zamay GS; Zamay SS; Smolyarova T; Tikhonova EP; Chen KH; Jeng US; Condorelli G; de Franciscis V; Groenhof G; Yang C; Moskovsky AA; Fedorov DG; Tomilin FN; Tan W; Alexeev Y; Berezovski MV; Kichkailo AS
Chemistry; 2022 Feb; 28(12):e202104481. PubMed ID: 35025110
[TBL] [Abstract][Full Text] [Related]
2. DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach.
Silwal AP; Thennakoon SKS; Arya SP; Postema RM; Jahan R; Phuoc CMT; Tan X
Theranostics; 2022; 12(12):5522-5536. PubMed ID: 35910791
[No Abstract] [Full Text] [Related]
3.
Morena F; Argentati C; Tortorella I; Emiliani C; Martino S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206794
[TBL] [Abstract][Full Text] [Related]
4. Methods and Applications of In Silico Aptamer Design and Modeling.
Buglak AA; Samokhvalov AV; Zherdev AV; Dzantiev BB
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182550
[TBL] [Abstract][Full Text] [Related]
5.
Chen Y; Yang X; Liu J; Zhang D; He J; Tang L; Li J; Xiang Q
Nucleosides Nucleotides Nucleic Acids; 2023; 42(2):105-118. PubMed ID: 35949145
[TBL] [Abstract][Full Text] [Related]
6. In-Silico Selection of Aptamer Targeting SARS-CoV-2 Spike Protein.
Lin YC; Chen WY; Hwu ET; Hu WP
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628622
[TBL] [Abstract][Full Text] [Related]
7. Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.
Saify Nabiabad H; Amini M; Demirdas S
Chem Biol Drug Des; 2022 Feb; 99(2):233-246. PubMed ID: 34714580
[TBL] [Abstract][Full Text] [Related]
8. [Efficient screening for 8-oxoguanine DNA glycosylase binding aptamers via capillary electrophoresis].
Han S; Zhao L; Yang G; Qu F
Se Pu; 2021 Jul; 39(7):721-729. PubMed ID: 34227370
[TBL] [Abstract][Full Text] [Related]
9. One Solution for All: Searching for Universal Aptamers for Constantly Mutating Spike Proteins of SARS-CoV-2.
Li J; Zhang Z; Amini R; Li Y
ChemMedChem; 2022 Jul; 17(13):e202200166. PubMed ID: 35491395
[TBL] [Abstract][Full Text] [Related]
10. Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.
Devi A; Chaitanya NSN
Mol Divers; 2022 Feb; 26(1):157-169. PubMed ID: 33389440
[TBL] [Abstract][Full Text] [Related]
11. Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection.
Rahman MS; Han MJ; Kim SW; Kang SM; Kim BR; Kim H; Lee CJ; Noh JE; Kim H; Lee JO; Jang SK
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375202
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanism of Interaction between DNA Aptamer and Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus 2 Variants Revealed by Steered Molecular Dynamics Simulations.
Ding X; Xu C; Zheng B; Yu H; Zheng P
Molecules; 2024 May; 29(10):. PubMed ID: 38792076
[TBL] [Abstract][Full Text] [Related]
13. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
Song Y; Song J; Wei X; Huang M; Sun M; Zhu L; Lin B; Shen H; Zhu Z; Yang C
Anal Chem; 2020 Jul; 92(14):9895-9900. PubMed ID: 32551560
[TBL] [Abstract][Full Text] [Related]
15. DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic.
Villa A; Brunialti E; Dellavedova J; Meda C; Rebecchi M; Conti M; Donnici L; De Francesco R; Reggiani A; Lionetti V; Ciana P
Pharmacol Res; 2022 Jan; 175():105982. PubMed ID: 34798263
[TBL] [Abstract][Full Text] [Related]
16. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.
Sun M; Liu S; Wei X; Wan S; Huang M; Song T; Lu Y; Weng X; Lin Z; Chen H; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10266-10272. PubMed ID: 33561300
[TBL] [Abstract][Full Text] [Related]
17. In silico molecular docking in DNA aptamer development.
Navien TN; Thevendran R; Hamdani HY; Tang TH; Citartan M
Biochimie; 2021 Jan; 180():54-67. PubMed ID: 33086095
[TBL] [Abstract][Full Text] [Related]
18. In-silico selection employing rigid docking and molecular dynamic simulation in selecting DNA aptamers against androgen receptor.
Thevendran R; Tang TH; Citartan M
Biotechnol J; 2023 Apr; 18(4):e2200092. PubMed ID: 36735817
[TBL] [Abstract][Full Text] [Related]
19. DNA aptamer selection for SARS-CoV-2 spike glycoprotein detection.
Martínez-Roque MA; Franco-Urquijo PA; García-Velásquez VM; Choukeife M; Mayer G; Molina-Ramírez SR; Figueroa-Miranda G; Mayer D; Alvarez-Salas LM
Anal Biochem; 2022 May; 645():114633. PubMed ID: 35247355
[TBL] [Abstract][Full Text] [Related]
20.
Escamilla-Gutiérrez A; Ribas-Aparicio RM; Córdova-Espinoza MG; Castelán-Vega JA
Nucleosides Nucleotides Nucleic Acids; 2021; 40(8):798-807. PubMed ID: 34323642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
